Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine.
Animals
Antiviral Agents
/ pharmacology
Biphenyl Compounds
/ pharmacology
Cell Culture Techniques
Chlorocebus aethiops
Dogs
Emetine
/ pharmacology
Enterovirus B, Human
/ drug effects
HIV-1
/ drug effects
Herpesvirus 2, Human
/ drug effects
Homoharringtonine
/ pharmacology
Humans
Indoles
Madin Darby Canine Kidney Cells
Niclosamide
/ pharmacology
Pyrroles
/ pharmacology
Vero Cells
Virus Diseases
/ drug therapy
Viruses
/ classification
antiviral agent
broad-spectrum antiviral
drug target
systems biology
virus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
18 10 2019
18 10 2019
Historique:
received:
11
09
2019
revised:
17
10
2019
accepted:
18
10
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
29
9
2020
Statut:
epublish
Résumé
Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FLUAV), niclosamide against HSV-2, brequinar against human immunodeficiency virus 1 (HIV-1), and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests.
Identifiants
pubmed: 31635418
pii: v11100964
doi: 10.3390/v11100964
pmc: PMC6832696
pii:
doi:
Substances chimiques
Antiviral Agents
0
Biphenyl Compounds
0
Indoles
0
Pyrroles
0
brequinar
5XL19F49H6
Homoharringtonine
6FG8041S5B
Niclosamide
8KK8CQ2K8G
obatoclax
QN4128B52A
Emetine
X8D5EPO80M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Antiviral Res. 2015 Feb;114:1-10
pubmed: 25451075
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27993855
Antiviral Res. 2017 Aug;144:196-204
pubmed: 28624461
Nature. 2018 May;557(7706):475-476
pubmed: 29789732
J Virol. 2019 Apr 3;93(8):
pubmed: 30700611
DNA Cell Biol. 2018 Feb;37(2):63-69
pubmed: 29148875
Viruses. 2018 Nov 01;10(11):
pubmed: 30388805
Front Pharmacol. 2018 Sep 20;9:1068
pubmed: 30294274
Antimicrob Agents Chemother. 2014 May;58(5):2905-11
pubmed: 24614368
Clin Microbiol Rev. 2016 Jul;29(3):695-747
pubmed: 27281742
Antiviral Res. 2019 Sep;169:104558
pubmed: 31302150
J Biol Chem. 2019 Sep 13;294(37):13740-13754
pubmed: 31346035
Antiviral Res. 2016 Nov;135:81-90
pubmed: 27742486
Viruses. 2019 Feb 20;11(2):
pubmed: 30791609
Viruses. 2013 Jan 11;5(1):127-49
pubmed: 23344560
Virology. 2004 Jun 20;324(1):67-73
pubmed: 15183054
J Med Chem. 2011 Dec 22;54(24):8670-80
pubmed: 22059983
Cell Death Dis. 2013 Jul 25;4:e742
pubmed: 23887633
Bioinformatics. 2017 Aug 1;33(15):2413-2415
pubmed: 28379339
PLoS Pathog. 2018 Jul 20;14(7):e1007188
pubmed: 30028873
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139-43
pubmed: 6306664
Antiviral Res. 2017 Mar;139:117-128
pubmed: 28049006
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Viruses. 2017 Sep 25;9(10):
pubmed: 28946654
Antiviral Res. 2018 Jun;154:174-182
pubmed: 29698664
J Gen Virol. 2008 Sep;89(Pt 9):2157-66
pubmed: 18753225
J Virol. 2019 May 29;93(12):
pubmed: 30918074
Antimicrob Agents Chemother. 2010 Sep;54(9):3686-95
pubmed: 20606073
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
Nat Commun. 2019 Jan 10;10(1):120
pubmed: 30631056
J Biol Chem. 2012 Oct 12;287(42):35324-32
pubmed: 22910914
Biol Open. 2018 Jan 29;7(1):null
pubmed: 29378701
J Virol. 2002 Feb;76(4):1856-65
pubmed: 11799180
Science. 2015 Apr 17;348(6232):282-3
pubmed: 25883340
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Curr Opin Infect Dis. 2015 Dec;28(6):596-602
pubmed: 26524332
J Microbiol. 2019 Jan;57(1):74-79
pubmed: 30456755
Emerg Microbes Infect. 2012 Dec;1(12):e46
pubmed: 26038413
PLoS One. 2013 Nov 04;8(11):e78425
pubmed: 24348901
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Planta Med. 2007 Jun;73(6):552-8
pubmed: 17458779
Br J Pharmacol. 2011 Sep;164(2):344-57
pubmed: 21418188
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444978
Front Immunol. 2019 Oct 04;10:2186
pubmed: 31636628
PLoS Pathog. 2016 Jun 23;12(6):e1005717
pubmed: 27336364
PLoS Negl Trop Dis. 2018 Aug 20;12(8):e0006715
pubmed: 30125275
Antiviral Res. 2017 Feb;138:68-78
pubmed: 27939840
Int J Biol Sci. 2018 Jul 13;14(10):1232-1244
pubmed: 30123072
Cell Discov. 2018 Jun 5;4:31
pubmed: 29872540
J Virol Methods. 2007 Aug;143(2):169-74
pubmed: 17420056
Molecules. 2015 Jun 22;20(6):11474-89
pubmed: 26111177
Drug Discov Today. 2019 May;24(5):1224-1228
pubmed: 30980905